Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial.

ABSTRACT:

Background

Generalized Anxiety Disorder (GAD) is one of the most common anxiety disorders treated in primary care, yet current therapies have limited efficacy and substantial side effects.

Purpose

To evaluate long-term chamomile (Matricaria chamomilla L.) use for prevention of GAD symptom relapse.

Methods

Outpatients from primary care practices and local communities with a primary diagnosis of moderate-to-severe GAD were enrolled for this two-phase study at a large US academic medical center. During Phase 1, eligible participants received 12 weeks of open-label therapy with chamomile pharmaceutical grade extract 1500mg (500mg capsule 3 times daily). During Phase 2, treatment responders were randomized to either 26 weeks of continuation chamomile therapy or placebo in

SUBMITTER: Mao JJ 

PROVIDER: S-EPMC5646235 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature